单位：[a]Department of Gastroenterology, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China临床科室国家中心消化分中心消化内科首都医科大学附属北京友谊医院[b]Department of Clinical and Biomedical Engineering, Oslo University Hospital, 4950 Nydalen, 0424 Oslo, Norway[c]Department of Emergencies and Critical Care, Oslo University Hospital, 4950 Nydalen, 0424 Oslo, Norway[d]Institute of Clinical Medicine, University of Oslo, 0316 Blindern, Oslo, Norway
Inflammation and oxidative stress play a significant role in the pathogenesis of nonalcoholic steatohepatitis (NASH). Ethyl pyruvate (EP) is a novel anti-inflammatory agent and a potent reactive oxygen species (ROS) scavenger. Therefore, EP supplemented in drinking water may alleviate experimental NASH in this study (even though 0.3% of EP cannot attenuate the simple non-aggressive fatty liver). The methionine-choline-deficient (MCD) diet was given to the C57BL/6 male mice for 3 weeks to induce NASH. The NASH animals were randomized into 3 treatment groups: animals in the MCD alone group were treated with normal drinking water alone; animals in the delayed EP group were given 3% (v/v) of EP supplemented in normal drinking water, the treatment started 10 days after MCD diet feeding; animals in the early EP therapy group were treated the same as the delayed EP group except that EP treatment started the same day when MCD diet was given; the control mice were fed with normal chow and treated with normal drinking water (n = 10 for each group). Compared to MCD group with normal drinking water, early EP treatment significantly decreased serum ALT and improved NASH histopathology; delayed EP therapy only attenuated NASH in 50% (5/10) of the animals. The beneficial effects were associated with decreased hepatic TNF-a and IL-6 mRNA expression on early 5 days, inhibited NF-kB activation, reduced liver tissue malondialdehyde levels, and decreased intestinal bacterial translocation (BT). In conclusion: EP supplemented in drinking water attenuates experimental NASH.
基金：
Nature and Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81302160]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类|2 区医学
小类|2 区药学3 区医学：研究与实验
最新[2025]版：
大类|2 区医学
小类|2 区医学：研究与实验2 区药学
JCR分区：
出版当年[2019]版：
Q1PHARMACOLOGY & PHARMACYQ1MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q1MEDICINE, RESEARCH & EXPERIMENTALQ1PHARMACOLOGY & PHARMACY
第一作者单位：[a]Department of Gastroenterology, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
通讯作者：
推荐引用方式(GB/T 7714)：
Sun X,Zhu S,Dong X,et al.Ethyl pyruvate supplemented in drinking water ameliorates experimental nonalcoholic steatohepatitis[J].BIOMEDICINE & PHARMACOTHERAPY.2021,137:doi:10.1016/j.biopha.2021.111392.
APA：
Sun, X,Zhu, S,Dong, X,Strand-Amundsen, R.J,Tonnessen, T.I&Yang, R.(2021).Ethyl pyruvate supplemented in drinking water ameliorates experimental nonalcoholic steatohepatitis.BIOMEDICINE & PHARMACOTHERAPY,137,
MLA：
Sun, X,et al."Ethyl pyruvate supplemented in drinking water ameliorates experimental nonalcoholic steatohepatitis".BIOMEDICINE & PHARMACOTHERAPY 137.(2021)
